Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Johnson and Johnson
Medtronic

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

DEFERASIROX Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Deferasirox, and what generic alternatives are available?

Deferasirox is a drug marketed by Actavis Elizabeth, Alembic Pharms Ltd, Alkem Labs Ltd, Bionpharma Inc, Msn Labs Pvt Ltd, Sun Pharm, Teva Pharms Usa, and Zydus Pharms. and is included in ten NDAs.

The generic ingredient in DEFERASIROX is deferasirox. There are twenty drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

US ANDA Litigation and Generic Entry Outlook for Deferasirox

  Start Trial

A generic version of DEFERASIROX was approved as deferasirox by ACTAVIS ELIZABETH on January 20th, 2020.

Drug patent expirations by year for DEFERASIROX
Recent Clinical Trials for DEFERASIROX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fondazione Italiana Sindromi Mielodisplastiche OnlusPhase 2
DisperSol Technologies, LLCPhase 2
National Cancer Institute (NCI)Phase 2

See all DEFERASIROX clinical trials

Recent Litigation for DEFERASIROX

Identify potential future generic entrants

District Court Litigation
Case NameDate
ALEMBIC PHARMACEUTICALS, LTD v. NOVARTIS PHARMACEUTICALS CORP.2019-11-27
Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc.2016-07-29
Novartis Pharmaceuticals Corporation v. Mylan Inc.2014-06-26

See all DEFERASIROX litigation

Paragraph IV (Patent) Challenges for DEFERASIROX
Tradename Dosage Ingredient NDA Submissiondate
JADENU TABLET;ORAL deferasirox 206910 2016-04-21
JADENU TABLET;ORAL deferasirox 206910 2015-10-19
EXJADE TABLET, FOR SUSPENSION;ORAL deferasirox 021882 2011-10-28

US Patents and Regulatory Information for DEFERASIROX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Elizabeth DEFERASIROX deferasirox TABLET, FOR SUSPENSION;ORAL 203560-001 Jan 26, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
Sun Pharm DEFERASIROX deferasirox TABLET, FOR SUSPENSION;ORAL 209782-003 Nov 20, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Teva Pharms Usa DEFERASIROX deferasirox TABLET;ORAL 209223-002 Nov 25, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Alkem Labs Ltd DEFERASIROX deferasirox TABLET, FOR SUSPENSION;ORAL 210519-001 Nov 20, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Alembic Pharms Ltd DEFERASIROX deferasirox TABLET, FOR SUSPENSION;ORAL 210060-001 Nov 20, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Bionpharma Inc DEFERASIROX deferasirox TABLET, FOR SUSPENSION;ORAL 210920-003 Nov 20, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Alembic Pharms Ltd DEFERASIROX deferasirox TABLET;ORAL 211824-002 Nov 20, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Merck
Harvard Business School
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.